FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2046389905> ?p ?o ?g. }

• W2046389905 abstract "Background: BMN 673 is the most potent and specific inhibitor of PARP1/2 in clinical development (IC50<1nM). In tumors genetically dependent on DNA repair by homologous recombination PARP inhibition induces synthetic lethality. PARP inhibition has also been shown to be effective in preclinical models of small cell lung cancer and Ewing sarcoma, possibly related to high PARP expression.Methods: Pharmacokinetics (PK), pharmacodynamics (PD), safety and anti-tumor activity of BMN 673 were evaluated in a 2-stage escalation/expansion study. Expansion included cohorts of pts with BRCA-related cancers, small cell lung cancer (SCLC) and Ewing sarcoma (ES).Results: (As of July 29, 2013) In escalation, 39 pts were enrolled in 9 cohorts from 25 to 1100 µg/d with 1000 µg/d being the MTD related to dose-limiting hematologic toxicity. 38 pts have been enrolled in expansion including 25 patients with BRCA related cancers. For all 77 (63F/14M) pts, median age (range) is 52 (18-81), PS, 0 (0-1) and # of prior therapies 4 (1-13). Eight ES, 7 SCLC and 48 patients with deleterious BRCA mutations and breast (n=18), ovarian (n=28) or pancreatic (n=2) cancer were enrolled. BMN 673 demonstrated good oral bioavailability and a long half-life supporting daily dosing (ASCO 2013 Abstract 2580). One related grade 4 toxicity (thrombocytopenia) occurred. Related grade 3 adverse events have included fatigue, anemia, neutropenia and thrombocytopenia, all in fewer than 15% of patients. Dose-related inhibition of PARP activity in PBMC's was observed. Response, reduction in neutrophils and platelets and the need for blood transfusions and dose reductions appear to correlate with BMN 673 exposure.Overall, the objective response (including CA-125) and clinical benefit response rates are for all BRCA patients are 60.4% and 81%, respectively. Treatment is ongoing in 5 of 7 SCLC patients and 2 of 8 ES patients with no objective responses observed yet.Conclusions: BMN 673 is well tolerated with high objective and clinical benefit response rates in heavily pre-treated ovarian and breast cancer pts with deleterious germline BRCA mutations. A phase 3 trial in metastatic breast cancer is underway.Clinicaltrial.gov ID: [NCT01286987][1]View this table:BRCA Breast and Ovarian CancerCitation Information: Mol Cancer Ther 2013;12(11 Suppl):C295.Citation Format: Zev A. Wainberg, Johann S. de Bono, Lida Mina, Jasgit Sachdev, Lauren Averett Byers, Rashmi Chugh, Charlie Zhang, Joshua W. Henshaw, Andrew Dorr, John Glaspy, Ramesh Ramanathan. Update on first-in-man trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr C295. [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT01286987&atom=%2Fmolcanther%2F12%2F11_Supplement%2FC295.atom" @default.
• W2046389905 created "2016-06-24" @default.
• W2046389905 creator A5006718606 @default.
• W2046389905 creator A5011633842 @default.
• W2046389905 creator A5016367638 @default.
• W2046389905 creator A5019473289 @default.
• W2046389905 creator A5047937790 @default.
• W2046389905 creator A5055462512 @default.
• W2046389905 creator A5067755477 @default.
• W2046389905 creator A5070265480 @default.
• W2046389905 creator A5072378199 @default.
• W2046389905 creator A5074225635 @default.
• W2046389905 creator A5080006341 @default.
• W2046389905 date "2013-11-01" @default.
• W2046389905 modified "2023-09-26" @default.
• W2046389905 title "Abstract C295: Update on first-in-man trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors." @default.
• W2046389905 doi "https://doi.org/10.1158/1535-7163.targ-13-c295" @default.
• W2046389905 hasPublicationYear "2013" @default.
• W2046389905 type Work @default.
• W2046389905 sameAs 2046389905 @default.
• W2046389905 citedByCount "6" @default.
• W2046389905 countsByYear W20463899052014 @default.
• W2046389905 countsByYear W20463899052015 @default.
• W2046389905 countsByYear W20463899052018 @default.
• W2046389905 countsByYear W20463899052020 @default.
• W2046389905 countsByYear W20463899052021 @default.
• W2046389905 crossrefType "proceedings-article" @default.
• W2046389905 hasAuthorship W2046389905A5006718606 @default.
• W2046389905 hasAuthorship W2046389905A5011633842 @default.
• W2046389905 hasAuthorship W2046389905A5016367638 @default.
• W2046389905 hasAuthorship W2046389905A5019473289 @default.
• W2046389905 hasAuthorship W2046389905A5047937790 @default.
• W2046389905 hasAuthorship W2046389905A5055462512 @default.
• W2046389905 hasAuthorship W2046389905A5067755477 @default.
• W2046389905 hasAuthorship W2046389905A5070265480 @default.
• W2046389905 hasAuthorship W2046389905A5072378199 @default.
• W2046389905 hasAuthorship W2046389905A5074225635 @default.
• W2046389905 hasAuthorship W2046389905A5080006341 @default.
• W2046389905 hasConcept C104317684 @default.
• W2046389905 hasConcept C111113717 @default.
• W2046389905 hasConcept C112705442 @default.
• W2046389905 hasConcept C121608353 @default.
• W2046389905 hasConcept C126322002 @default.
• W2046389905 hasConcept C143998085 @default.
• W2046389905 hasConcept C182979987 @default.
• W2046389905 hasConcept C197934379 @default.
• W2046389905 hasConcept C2777063308 @default.
• W2046389905 hasConcept C2779138821 @default.
• W2046389905 hasConcept C2779962180 @default.
• W2046389905 hasConcept C29730261 @default.
• W2046389905 hasConcept C55493867 @default.
• W2046389905 hasConcept C71924100 @default.
• W2046389905 hasConcept C82381507 @default.
• W2046389905 hasConcept C86803240 @default.
• W2046389905 hasConcept C90924648 @default.
• W2046389905 hasConcept C98274493 @default.
• W2046389905 hasConceptScore W2046389905C104317684 @default.
• W2046389905 hasConceptScore W2046389905C111113717 @default.
• W2046389905 hasConceptScore W2046389905C112705442 @default.
• W2046389905 hasConceptScore W2046389905C121608353 @default.
• W2046389905 hasConceptScore W2046389905C126322002 @default.
• W2046389905 hasConceptScore W2046389905C143998085 @default.
• W2046389905 hasConceptScore W2046389905C182979987 @default.
• W2046389905 hasConceptScore W2046389905C197934379 @default.
• W2046389905 hasConceptScore W2046389905C2777063308 @default.
• W2046389905 hasConceptScore W2046389905C2779138821 @default.
• W2046389905 hasConceptScore W2046389905C2779962180 @default.
• W2046389905 hasConceptScore W2046389905C29730261 @default.
• W2046389905 hasConceptScore W2046389905C55493867 @default.
• W2046389905 hasConceptScore W2046389905C71924100 @default.
• W2046389905 hasConceptScore W2046389905C82381507 @default.
• W2046389905 hasConceptScore W2046389905C86803240 @default.
• W2046389905 hasConceptScore W2046389905C90924648 @default.
• W2046389905 hasConceptScore W2046389905C98274493 @default.
• W2046389905 hasLocation W20463899051 @default.
• W2046389905 hasOpenAccess W2046389905 @default.
• W2046389905 hasPrimaryLocation W20463899051 @default.
• W2046389905 hasRelatedWork W2112241575 @default.
• W2046389905 hasRelatedWork W2147154862 @default.
• W2046389905 hasRelatedWork W2241936991 @default.
• W2046389905 hasRelatedWork W2331255506 @default.
• W2046389905 hasRelatedWork W2395647884 @default.
• W2046389905 hasRelatedWork W2399357550 @default.
• W2046389905 hasRelatedWork W2601536553 @default.
• W2046389905 hasRelatedWork W2621701159 @default.
• W2046389905 hasRelatedWork W2783778570 @default.
• W2046389905 hasRelatedWork W2799763448 @default.
• W2046389905 hasRelatedWork W2887083728 @default.
• W2046389905 hasRelatedWork W2942638947 @default.
• W2046389905 hasRelatedWork W2954172273 @default.
• W2046389905 hasRelatedWork W2955619322 @default.
• W2046389905 hasRelatedWork W2994057850 @default.
• W2046389905 hasRelatedWork W3012456582 @default.
• W2046389905 hasRelatedWork W3013924071 @default.
• W2046389905 hasRelatedWork W3129303686 @default.
• W2046389905 hasRelatedWork W3130256467 @default.
• W2046389905 hasRelatedWork W3137779807 @default.
• W2046389905 isParatext "false" @default.
• W2046389905 isRetracted "false" @default.
• W2046389905 magId "2046389905" @default.

• next